Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination.
dc.contributor.author | Freel, SA | |
dc.contributor.author | Lamoreaux, L | |
dc.contributor.author | Chattopadhyay, PK | |
dc.contributor.author | Saunders, K | |
dc.contributor.author | Zarkowsky, D | |
dc.contributor.author | Overman, RG | |
dc.contributor.author | Ochsenbauer, C | |
dc.contributor.author | Edmonds, TG | |
dc.contributor.author | Kappes, JC | |
dc.contributor.author | Cunningham, CK | |
dc.contributor.author | Denny, TN | |
dc.contributor.author | Weinhold, KJ | |
dc.contributor.author | Ferrari, G | |
dc.contributor.author | Haynes, BF | |
dc.contributor.author | Koup, RA | |
dc.contributor.author | Graham, BS | |
dc.contributor.author | Roederer, M | |
dc.contributor.author | Tomaras, GD | |
dc.date.accessioned | 2021-01-04T21:41:42Z | |
dc.date.available | 2021-01-04T21:41:42Z | |
dc.date.issued | 2010-05 | |
dc.date.updated | 2021-01-04T21:41:41Z | |
dc.description.abstract | Control of HIV-1 replication following nonsterilizing HIV-1 vaccination could be achieved by vaccine-elicited CD8(+) T-cell-mediated antiviral activity. To date, neither the functional nor the phenotypic profiles of CD8(+) T cells capable of this activity are clearly understood; consequently, little is known regarding the ability of vaccine strategies to elicit them. We used multiparameter flow cytometry and viable cell sorts from phenotypically defined CD8(+) T-cell subsets in combination with a highly standardized virus inhibition assay to evaluate CD8(+) T-cell-mediated inhibition of viral replication. Here we show that vaccination against HIV-1 Env and Gag-Pol by DNA priming followed by recombinant adenovirus type 5 (rAd5) boosting elicited CD8(+) T-cell-mediated antiviral activity against several viruses with either lab-adapted or transmitted virus envelopes. As it did for chronically infected virus controllers, this activity correlated with HIV-1-specific CD107a or macrophage inflammatory protein 1beta (MIP-1beta) expression from HIV-1-specific T cells. Moreover, for vaccinees or virus controllers, purified memory CD8(+) T cells from a wide range of differentiation stages were capable of significantly inhibiting virus replication. Our data define attributes of an antiviral CD8(+) T-cell response that may be optimized in the search for an efficacious HIV-1 vaccine. | |
dc.identifier | JVI.00138-10 | |
dc.identifier.issn | 0022-538X | |
dc.identifier.issn | 1098-5514 | |
dc.identifier.uri | ||
dc.language | eng | |
dc.publisher | American Society for Microbiology | |
dc.relation.ispartof | Journal of virology | |
dc.relation.isversionof | 10.1128/jvi.00138-10 | |
dc.subject | T-Lymphocyte Subsets | |
dc.subject | CD8-Positive T-Lymphocytes | |
dc.subject | Humans | |
dc.subject | Adenoviridae | |
dc.subject | HIV-1 | |
dc.subject | HIV Infections | |
dc.subject | Vaccines, DNA | |
dc.subject | AIDS Vaccines | |
dc.subject | Immunization, Secondary | |
dc.subject | Vaccination | |
dc.subject | Flow Cytometry | |
dc.subject | Transduction, Genetic | |
dc.title | Phenotypic and functional profile of HIV-inhibitory CD8 T cells elicited by natural infection and heterologous prime/boost vaccination. | |
dc.type | Journal article | |
duke.contributor.orcid | Saunders, K|0000-0001-7399-7954 | |
duke.contributor.orcid | Cunningham, CK|0000-0002-7725-3052 | |
duke.contributor.orcid | Ferrari, G|0000-0001-7747-3349 | |
duke.contributor.orcid | Tomaras, GD|0000-0001-8076-1931 | |
pubs.begin-page | 4998 | |
pubs.end-page | 5006 | |
pubs.issue | 10 | |
pubs.organisational-group | School of Medicine | |
pubs.organisational-group | Duke Cancer Institute | |
pubs.organisational-group | Duke Human Vaccine Institute | |
pubs.organisational-group | Immunology | |
pubs.organisational-group | Pathology | |
pubs.organisational-group | Surgery, Surgical Sciences | |
pubs.organisational-group | Duke | |
pubs.organisational-group | Institutes and Centers | |
pubs.organisational-group | Basic Science Departments | |
pubs.organisational-group | Clinical Science Departments | |
pubs.organisational-group | Surgery | |
pubs.organisational-group | Duke Global Health Institute | |
pubs.organisational-group | Pediatrics, Infectious Diseases | |
pubs.organisational-group | University Institutes and Centers | |
pubs.organisational-group | Institutes and Provost's Academic Units | |
pubs.organisational-group | Pediatrics | |
pubs.organisational-group | Medicine, Duke Human Vaccine Institute | |
pubs.organisational-group | Medicine | |
pubs.organisational-group | Molecular Genetics and Microbiology | |
pubs.organisational-group | Duke Innovation & Entrepreneurship | |
pubs.organisational-group | Initiatives | |
pubs.organisational-group | Staff | |
pubs.publication-status | Published | |
pubs.volume | 84 |